封面
市場調查報告書
商品編碼
925282

地中海型貧血治療市場 - 成長,趨勢,預測 (2020 - 2025)

Thalassemia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球地中海型貧血治療市場在2020年~2025年間,預測將以7.6%的年複合成長率擴大。隨著地中海型貧血的盛行率上升,比骨髓移植更方便的螯合療法繼續引起人們的關注,生物技術和製藥公司加大研發投入正在推動市場增長。

本報告提供地中海型貧血治療的世界市場調查,提供市場概要,各類型,終端用戶,各地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄<

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各治療類型
    • 輸血
    • 鐵螫合物療法
    • 葉酸補充品
    • 其他
  • 各類型
    • Alpha地中海型貧血
    • β地中海型貧血
  • 各終端用戶
    • 醫院
    • 研究機關
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bluebird Bio
    • IONIS Pharmaceuticals
    • Novartis AG
    • Bellicum Pharmaceuticals
    • ApoPharma Inc
    • Pfizer, Inc.
    • Acceleron Pharma, Inc.
    • Kiadis Pharma
    • SG Phrma Pvt. Lmt.

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 67808

The thalassemia treatment market studied was projected to grow with a CAGR of nearly 7.6% over the forecast period. The major factors attributing to the growth of the market are increasing prevalence of thalassemia and also growing awareness to treat thalassemia. According to National Center on Birth Defects and Developmental Disabilities, thalassemia, affects at least 1,000 people in the United States. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companies boosting the market growth. Chelation therapy and blood transfusion are the conventional treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion method for purifying blood, raise the possibility of curing thalassemia in patients. However the high cost of the treatment is major drawback for the market growth.

Key Market Trends

Chelation Therapy segment is expected to be the Fastest Growing Segment

  • Iron overload is the main cause of sickness for thalassemia patients. Even non- transfused patients develop iron overload secondary to boosted intestinal absorption of dietary iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation.
  • The segment is projected to expand at an exponential growth rate during the forecast period. The major factors driving the growth of the segment are increasing incidence of thalassemia patients and increasing research and development investments.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall thalassemia treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. The United States has the main share due to the rising awareness about the condition and increasing number of populations with thalassemia carrier gene, and growth in birth rates due to variation of genes among the population.

Competitive Landscape

The thalassemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.,

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Thalassemia
    • 4.2.2 Increasing Awareness of Thalassemia Treatment
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Blood Transfusions
    • 5.1.2 Iron Chelation Therapy
    • 5.1.3 Folic Acid Supplements
    • 5.1.4 Others
  • 5.2 By Disease Type
    • 5.2.1 Alpha Thalassemia
    • 5.2.2 Beta Thalassemia
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Research Institutes
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bluebird Bio
    • 6.1.2 IONIS Pharmaceuticals
    • 6.1.3 Novartis AG
    • 6.1.4 Bellicum Pharmaceuticals
    • 6.1.5 ApoPharma Inc
    • 6.1.6 Pfizer, Inc.
    • 6.1.7 Acceleron Pharma, Inc.
    • 6.1.8 Kiadis Pharma
    • 6.1.9 SG Phrma Pvt. Lmt.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS